CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

LivaNova Q3 revenue beats estimates on cardiopulmonary segment strength 

By Reuters News


Overview

  • UK medical device maker's Q3 revenue rose 9.9%, beating analyst expectations

  • Adjusted EPS for Q3 beat consensus, rising to $1.23

  • Company raised full-year 2026 revenue and adjusted EPS guidance


Outlook

  • LivaNova raises full-year 2026 revenue growth guidance to 9%-10% constant-currency, from 8%-9%

  • Company now expects full-year 2026 adjusted diluted EPS of $4.40-$4.50, up from $4.30-$4.40

  • Company maintains full-year 2026 adjusted free cash flow guidance at $140 mln to $160 mln


Result Drivers

  • CARDIOPULMONARY DEMAND - Co said Cardiopulmonary segment revenue rose 10.9%, driven by strong consumables demand and Essenz Perfusion System sales, as well as favorable realized price

  • NEUROMODULATION GROWTH - Neuromodulation segment revenue rose 11.1%, with growth across all regions, driven by higher volume and favorable realized price

  • OXYGENATOR CAPACITY EXPANSION - Co achieved operational production on new oxygenator manufacturing line to address strong customer demand


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$393.10 mln

$381.07 mln (9 Analysts)

Q3 Adjusted EPS

Beat

$1.23

$1.06 (9 Analysts)

Q3 EPS

$0.11


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for LivaNova PLC is $91.50, about 14.5% above its November 3 closing price of $79.90

  • The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 18 three months ago


Reuters Recommended Reads

  • Nov 4 - UK's Smith & Nephew misses Q3 revenue estimates, cuts outlook on slower US orthopaedics market

  • Nov 4 - Smith+Nephew cuts outlook after failed orthopaedics deal talks with J&J

  • Nov 2 - Denmark medical devices maker Coloplast's Q4 revenue rises


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.